214 related articles for article (PubMed ID: 26766162)
1. Pathogen-reduced Ebola virus convalescent plasma: first steps towards standardization of manufacturing and quality control including assessment of Ebola-specific neutralizing antibodies.
Geisen C; Kann G; Strecker T; Wolf T; Schüttfort G; van Kraaij M; MacLennan S; Rummler S; Weinigel C; Eickmann M; Fehling SK; Krähling V; Seidl C; Seifried E; Schmidt M; Schäfer R
Vox Sang; 2016 May; 110(4):329-35. PubMed ID: 26766162
[TBL] [Abstract][Full Text] [Related]
2. Specific neutralizing response in plasma from convalescent patients of Ebola Virus Disease against the West Africa Makona variant of Ebola virus.
Luczkowiak J; Arribas JR; Gómez S; Jiménez-Yuste V; de la Calle F; Viejo A; Delgado R
Virus Res; 2016 Feb; 213():224-229. PubMed ID: 26739425
[TBL] [Abstract][Full Text] [Related]
3. Characterization of Ebola convalescent plasma donor immune response and psoralen treated plasma in the United States.
Dean CL; Hooper JW; Dye JM; Zak SE; Koepsell SA; Corash L; Benjamin RJ; Kwilas S; Bonds S; Winkler AM; Kraft CS
Transfusion; 2020 May; 60(5):1024-1031. PubMed ID: 32129478
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of Convalescent Plasma for Ebola Virus Disease in Guinea.
van Griensven J; Edwards T; de Lamballerie X; Semple MG; Gallian P; Baize S; Horby PW; Raoul H; Magassouba N; Antierens A; Lomas C; Faye O; Sall AA; Fransen K; Buyze J; Ravinetto R; Tiberghien P; Claeys Y; De Crop M; Lynen L; Bah EI; Smith PG; Delamou A; De Weggheleire A; Haba N;
N Engl J Med; 2016 Jan; 374(1):33-42. PubMed ID: 26735992
[TBL] [Abstract][Full Text] [Related]
5. Treatment of blood with a pathogen reduction technology using ultraviolet light and riboflavin inactivates Ebola virus in vitro.
Cap AP; Pidcoke HF; Keil SD; Staples HM; Anantpadma M; Carrion R; Davey RA; Frazer-Abel A; Taylor AL; Gonzales R; Patterson JL; Goodrich RP
Transfusion; 2016 Mar; 56 Suppl 1(Suppl 1):S6-15. PubMed ID: 27001363
[TBL] [Abstract][Full Text] [Related]
6. Successful post-exposure prophylaxis of Ebola infected non-human primates using Ebola glycoprotein-specific equine IgG.
Pyankov OV; Setoh YX; Bodnev SA; Edmonds JH; Pyankova OG; Pyankov SA; Pali G; Belford S; Lu L; La M; Lovrecz G; Volchkova VA; Chappell KJ; Watterson D; Marsh G; Young PR; Agafonov AA; Farmer JF; Volchkov VE; Suhrbier A; Khromykh AA
Sci Rep; 2017 Feb; 7():41537. PubMed ID: 28155869
[TBL] [Abstract][Full Text] [Related]
7. Broad Neutralizing Activity Against Ebolaviruses Lacking the Mucin-Like Domain in Convalescent Plasma Specimens From Patients With Ebola Virus Disease.
Luczkowiak J; Lasala F; Mora-Rillo M; Arribas JR; Delgado R
J Infect Dis; 2018 Nov; 218(suppl_5):S574-S581. PubMed ID: 29939289
[TBL] [Abstract][Full Text] [Related]
8. Detection, characterization, and enrollment of donors of Ebola convalescent plasma in Sierra Leone.
Tedder RS; Samuel D; Dicks S; Scott JT; Ijaz S; Smith CC; Adaken C; Cole C; Baker S; Edwards T; Kamara P; Kargbo O; Niazi S; Nwakanma D; d'Alessandro U; Burch G; Doughty H; Brown CS; Andrews N; Glynn JR; van Griensven J; ; Pollakis G; Paxton WA; Semple MG
Transfusion; 2018 May; 58(5):1289-1298. PubMed ID: 29572862
[TBL] [Abstract][Full Text] [Related]
9. Use of convalescent plasma in Ebola virus infection.
Garraud O
Transfus Apher Sci; 2017 Feb; 56(1):31-34. PubMed ID: 28094110
[TBL] [Abstract][Full Text] [Related]
10. Pan-ebolavirus and Pan-filovirus Mouse Monoclonal Antibodies: Protection against Ebola and Sudan Viruses.
Holtsberg FW; Shulenin S; Vu H; Howell KA; Patel SJ; Gunn B; Karim M; Lai JR; Frei JC; Nyakatura EK; Zeitlin L; Douglas R; Fusco ML; Froude JW; Saphire EO; Herbert AS; Wirchnianski AS; Lear-Rooney CM; Alter G; Dye JM; Glass PJ; Warfield KL; Aman MJ
J Virol; 2016 Jan; 90(1):266-78. PubMed ID: 26468533
[TBL] [Abstract][Full Text] [Related]
11. Isolation of potent neutralizing antibodies from a survivor of the 2014 Ebola virus outbreak.
Bornholdt ZA; Turner HL; Murin CD; Li W; Sok D; Souders CA; Piper AE; Goff A; Shamblin JD; Wollen SE; Sprague TR; Fusco ML; Pommert KB; Cavacini LA; Smith HL; Klempner M; Reimann KA; Krauland E; Gerngross TU; Wittrup KD; Saphire EO; Burton DR; Glass PJ; Ward AB; Walker LM
Science; 2016 Mar; 351(6277):1078-83. PubMed ID: 26912366
[TBL] [Abstract][Full Text] [Related]
12. Safety and immunogenicity of the rVSV∆G-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled, dose-response study.
Heppner DG; Kemp TL; Martin BK; Ramsey WJ; Nichols R; Dasen EJ; Link CJ; Das R; Xu ZJ; Sheldon EA; Nowak TA; Monath TP;
Lancet Infect Dis; 2017 Aug; 17(8):854-866. PubMed ID: 28606591
[TBL] [Abstract][Full Text] [Related]
13. Design and analysis considerations in the Ebola_Tx trial evaluating convalescent plasma in the treatment of Ebola virus disease in Guinea during the 2014-2015 outbreak.
Edwards T; Semple MG; De Weggheleire A; Claeys Y; De Crop M; Menten J; Ravinetto R; Temmerman S; Lynen L; Bah EI; Smith PG; van Griensven J;
Clin Trials; 2016 Feb; 13(1):13-21. PubMed ID: 26768570
[TBL] [Abstract][Full Text] [Related]
14. Passive Immunotherapy: Assessment of Convalescent Serum Against Ebola Virus Makona Infection in Nonhuman Primates.
Mire CE; Geisbert JB; Agans KN; Thi EP; Lee AC; Fenton KA; Geisbert TW
J Infect Dis; 2016 Oct; 214(suppl 3):S367-S374. PubMed ID: 27571900
[TBL] [Abstract][Full Text] [Related]
15. Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody.
Corti D; Misasi J; Mulangu S; Stanley DA; Kanekiyo M; Wollen S; Ploquin A; Doria-Rose NA; Staupe RP; Bailey M; Shi W; Choe M; Marcus H; Thompson EA; Cagigi A; Silacci C; Fernandez-Rodriguez B; Perez L; Sallusto F; Vanzetta F; Agatic G; Cameroni E; Kisalu N; Gordon I; Ledgerwood JE; Mascola JR; Graham BS; Muyembe-Tamfun JJ; Trefry JC; Lanzavecchia A; Sullivan NJ
Science; 2016 Mar; 351(6279):1339-42. PubMed ID: 26917593
[TBL] [Abstract][Full Text] [Related]
16. Ebola virus convalescent blood products: where we are now and where we may need to go.
Burnouf T; Seghatchian J
Transfus Apher Sci; 2014 Oct; 51(2):120-5. PubMed ID: 25457751
[TBL] [Abstract][Full Text] [Related]
17. Potent neutralizing monoclonal antibodies against Ebola virus infection.
Zhang Q; Gui M; Niu X; He S; Wang R; Feng Y; Kroeker A; Zuo Y; Wang H; Wang Y; Li J; Li C; Shi Y; Shi X; Gao GF; Xiang Y; Qiu X; Chen L; Zhang L
Sci Rep; 2016 May; 6():25856. PubMed ID: 27181584
[TBL] [Abstract][Full Text] [Related]
18. Convalescent plasma: new evidence for an old therapeutic tool?
Marano G; Vaglio S; Pupella S; Facco G; Catalano L; Liumbruno GM; Grazzini G
Blood Transfus; 2016 Mar; 14(2):152-7. PubMed ID: 26674811
[TBL] [Abstract][Full Text] [Related]
19. Apheresis for collection of Ebola convalescent plasma in Liberia.
Brown JF; Rowe K; Zacharias P; van Hasselt J; Dye JM; Wohl DA; Fischer WA; Cunningham CK; Thielman NM; Hoover DL
J Clin Apher; 2017 Jun; 32(3):175-181. PubMed ID: 27393614
[TBL] [Abstract][Full Text] [Related]
20. A heterologous prime-boost Ebola virus vaccine regimen induces durable neutralizing antibody response and prevents Ebola virus-like particle entry in mice.
Chen T; Li D; Song Y; Yang X; Liu Q; Jin X; Zhou D; Huang Z
Antiviral Res; 2017 Sep; 145():54-59. PubMed ID: 28733113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
